M

Merck

Makes medicines, vaccines and animal treatments

Biologics Process R&D Senior Scientist

Full-TimeUpdated on 10/23/2026Deadline 11/25/26
$117k - $184.2k+ Annual bonus + Long-term incentive
Mid, Senior
PhD, Bachelor of Science (BS), Master of Science (MS)
Rahway, NJ, USA
In PersonRole is based in Rahway, New Jersey; domestic relocation is offered. Travel requirement is 10%.
Biology & BiotechBioprocess & Biomanufacturing
H1B Sponsorship Available

About the job

Requirements
  • A B.S. with 4 years, an M.S. with 3 years, or a PhD with 0+ years of relevant experience (or expected PhD graduation by June 2027) in Chemical Engineering, Biochemical Engineering, Biomedical Engineering, Biotechnology, Biochemistry, Biology, Microbiology, or related fields.
  • Ability to design and execute hands-on laboratory and/or in silico experiments.
  • Proficiency with statistical design and analysis tools.
  • Ability to work in matrixed teams and collaborate cross-functionally with diverse partners.
  • Ability to think critically and solve and troubleshoot problems.
  • Relevant experience in upstream and/or downstream bioprocessing.
  • Upstream knowledge of recombinant protein expression, metabolic pathways, biochemistry, and cell culture.
  • Understanding of basic bioreactor principles and mass transfer kinetics.
  • Understanding of cell and molecular biology.
  • Downstream scientific knowledge of protein properties and purification.
  • Understanding of unit operations such as chromatography, filtration, crystallization, precipitation, adsorption, and mixing.
  • Required skills include adaptability, bioprocessing, cross-functional teamwork, data analysis, drug delivery technology, flow cytometry, high-throughput screening, innovative thinking, interpersonal relationships, molecular biology techniques, multi-color flow cytometry, preformulation, process optimization, protein biochemistry, and protein purification.
Responsibilities
  • Develop innovative and disruptive technologies for next-generation biologic manufacturing processes.
  • Apply scientific principles and data analyses to solve problems related to developing robust, cost-effective processes.
  • Develop and characterize robust processes for delivering multi-kilogram quantities of medicines.
  • Design and conduct laboratory and/or pilot-scale studies to support mechanistic understanding, scale-up, and transfer of processes to manufacturing.
  • Work with a collaborative, cross-functional team of scientists and engineers to advance the biologics pipeline from early- to late-stage development.
  • Partner with groups in research and manufacturing divisions.
  • Represent the functional area in cross-functional teams.
  • Train and mentor junior scientists in experimental design, execution, and data interpretation.
  • Contribute to a safe and compliant laboratory work environment.
Desired Qualifications
  • History of external presentations and/or publications in peer-reviewed journals.
  • Experience with data science, modeling, machine learning, artificial intelligence, and programming languages.
  • Experience evaluating and introducing novel technologies and analytical tools in process development and manufacturing.
  • Knowledge of protein biochemistry, biophysics, and conjugation techniques.
  • Experience with vector construction, genetic engineering, and systems biology.
  • Knowledge of cell-line development for protein expression in mammalian systems and suspension cell culture.
  • Hands-on experience with RNA and whole-genome sequencing and bioinformatics analysis.
  • Experience with high-throughput experimentation using automation platforms.
  • Familiarity with feed and media development for large-scale recombinant protein expression in mammalian systems.
  • Knowledge of Quality by Design, Process Characterization, and Control Strategy development.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.

CNBC
Oct 20th, 2026
Trump administration reaches diesel supply agreement with Russia ahead of US midterm elections.

Trump administration reaches diesel supply agreement with Russia ahead of US midterm elections. US President Donald Trump and Russian President Vladimir Putin have reached an agreement to release Russian diesel fuel into American and international markets in an effort to lower energy prices before November's midterm elections. The arrangement has drawn scrutiny over its implications for sanctions against Russia and the continuing war in Ukraine. Iranian Forces Target Strait of Hormuz Shipping in Reported Effort to Influence US Elections Iranian military and allied forces are reportedly using new tactics against commercial shipping in the Strait of Hormuz, with the stated aim of driving up global oil prices and increasing political pressure ahead of the US midterm elections. The activity raises concerns about maritime security and energy supplies along a critical international shipping route. Federal Judge Extends Order Protecting White House Access for CNN, Politico and MS NOW A US federal judge has extended a preliminary injunction preventing the Trump administration from revoking White House press credentials held by reporters from CNN, Politico and MS NOW. The ruling preserves journalists' access while recognizing the government's authority to protect classified national security information. US Regulators Fine Bank of America $1.2 Billion Over Financial Compliance Failures Federal regulators have imposed a $1.2 billion penalty on Bank of America over failures to monitor and report suspicious financial activity. The enforcement action focuses on shortcomings in the bank's compliance procedures and underscores regulatory scrutiny of financial crime prevention. US Justice Department Investigates Suspected Espionage Device Found in OpenAI Conference Room Federal investigators are examining an encrypted recording device reportedly discovered inside a television in an executive conference room at OpenAI. The investigation centers on potential corporate espionage and raises questions about the security of sensitive information within the artificial intelligence company. Trump Suggests Canada Could Become 51st US State, Drawing Canadian Opposition US President Donald Trump has suggested during a campaign rally in San Antonio, Texas, that Canada could eventually become America's 51st state, citing trade relations between the two countries. The remarks prompted objections from Canadian officials and renewed diplomatic controversy. US Ambassador Kimberly Guilfoyle Resigns From Post in Greece Following White House Request Kimberly Guilfoyle has resigned as US ambassador to Greece after the White House requested her departure following a series of damaging reports. Her resignation leaves the State Department seeking new leadership for its diplomatic mission in Athens. Merck Opens $550 Million Pharmaceutical Research Facility in Pennsylvania US pharmaceutical company Merck has inaugurated a $550 million bioanalytical research and development facility in West Point, Pennsylvania. The investment expands the company's domestic research infrastructure and supports advanced pharmaceutical development in the region.